SCHEMBL27088170

SCHEMBL27088170

COc1ncnc(C2CC2)c1-c1ncc2c(n1)N(Cc1ccc(-c3nc(C(F)(F)F)cn3C(F)F)cc1)CC(=O)N2C

nearest known ligand 0.61

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ USP1 O94782 20/20 0.61
▸ WDR48 Q8TAF3 6/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30033624 1.00 USP1 (0.61) USP1WDR48
SCHEMBL29295819 0.95 USP1 (0.55) USP1WDR48
SCHEMBL27088273 0.95 USP1 (0.68) USP1WDR48
SCHEMBL30693857 0.95 USP1 (0.68) USP1WDR48
SCHEMBL30693891 0.92 USP1 (0.68) USP1WDR48
SCHEMBL27088179 0.92 USP1 (0.68) USP1WDR48
SCHEMBL27088278 0.91 USP1 (0.67) USP1WDR48
SCHEMBL30693898 0.91 USP1 (0.67) USP1WDR48
SCHEMBL29295825 0.90 USP1 (0.62) USP1WDR48
SCHEMBL31607477 0.88 USP1 (0.65) USP1WDR48

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226107-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 — — US disclosed
US-20240226107-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 — — US disclosed
US-20240226107-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 — — US disclosed
EP-4321515-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR Simcere Zaiming Pharmaceutical Co., Ltd. (CN) 2024-02-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226107-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR USP1, USP2, USP3 USP1 1/4885WDR48 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback